Eli Lilly (LLY)
1,273.46
-33.23 (-2.54%)
NYSE · Last Trade: Oct 24th, 4:04 AM EDT
News & Press Releases
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)fool.com
These drugmakers are capitalizing on their pipeline successes.
Via The Motley Fool · October 23, 2026
Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leaderinvestors.com
Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.
Via Investor's Business Daily · October 23, 2026
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomachmarketbeat.com
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Via MarketBeat · October 23, 2026
The S&P 500 May Depend on the Fortunes of These 3 Companies Right Now. Here’s the Good News and the Bad News for Investors.fool.com
These companies make up about 20% of the index.
Via The Motley Fool · October 23, 2026
Eli Lilly & Co (NYSE:LLY) Offers Dividend Quality for Growth-Focused Income Investorschartmill.com
Via Chartmill · October 19, 2026
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · October 22, 2026
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?fool.com
Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
Via The Motley Fool · October 22, 2026
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?fool.com
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.
Via The Motley Fool · October 22, 2026
Vanguard Health Care ETF vs iShares U.S. Healthcare ETFfool.com
VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification.
Via The Motley Fool · October 21, 2026
Where Will Novo Stock Be in 10 Years?fool.com
The company may lean on its core therapeutic area to help it overcome recent headwinds.
Via The Motley Fool · October 21, 2026
Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highsmarketbeat.com
Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.
Via MarketBeat · October 21, 2026
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026fool.com
The market has rewarded this biotech for its breakthroughs.
Via The Motley Fool · October 21, 2026
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?fool.com
Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.
Via The Motley Fool · October 21, 2026
Here's What I'm Planning With My Eli Lilly Positionfool.com
The pharmaceutical industry is relatively less correlated to the rest of the economy, and that's a diversification benefit for investors.
Via The Motley Fool · October 20, 2026
Stock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5%fool.com
On Oct. 20, 2026, major U.S. indexes gained as falling oil prices boosted blue chips and semiconductors edged upwards.
Via The Motley Fool · October 20, 2026
S&P 500 Top Movers: Gainers and Losers From Today's US Sessionchartmill.com
Via Chartmill · October 20, 2026
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via StockStory · October 20, 2026
Is Eli Lilly Stock a Buy Right Now?fool.com
Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.
Via The Motley Fool · October 19, 2026
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Marketfool.com
Is this company the biggest dark horse in the chronic weight management space?
Via The Motley Fool · October 19, 2026
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winningmarketbeat.com
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via MarketBeat · October 19, 2026
What a Mixed Midterm Result Could Mean for These 2 Health Care ETFsmarketbeat.com
Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.
Via MarketBeat · October 19, 2026
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive Itfool.com
Buffett has warned about "gambling" in the market.
Via The Motley Fool · October 19, 2026
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.fool.com
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.
Via The Motley Fool · October 18, 2026
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?fool.com
Novo is facing some headwinds, but it has a plan to overcome them.
Via The Motley Fool · October 18, 2026
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.fool.com
It was Griffin's biggest add for Citadel last quarter.
Via The Motley Fool · October 18, 2026